CBP-1018 is a PDC (peptide-drug conjugate) formed by conjugating Monomethyl auristatin E to a dual-targeting ligand of FLOR1 / PSMA (prostate-specific membrane antigen) via a linker. CBP-1018 binds to FLOR1 and prostate-specific membrane antigen ( PSMA ). CBP-1018 is applicable to the research of solid tumors and metastatic castration-resistant prostate cancer [1] [2].
In Vitro, CBP-1018 exhibits connexin-dependent instability in plasma[1]. CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA)[1].
References:
[1]. Li X, et al. LC-MS/MS method for dual-ligand peptide-drug CBP-1018 and its deconjugated payload MMAE including sample stabilization strategy for its MC-Val-Cit-PABC linker. Talanta. 2024;279:126596.
[2]. Li K, et al. Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC)[J]. 2025.
In Vitro, CBP-1018 exhibits connexin-dependent instability in plasma[1]. CBP-1018 binds to FLOR1 and prostate-specific membrane antigen (PSMA)[1].
References:
[1]. Li X, et al. LC-MS/MS method for dual-ligand peptide-drug CBP-1018 and its deconjugated payload MMAE including sample stabilization strategy for its MC-Val-Cit-PABC linker. Talanta. 2024;279:126596.
[2]. Li K, et al. Updated results from a phase I/II study of CBP-1018, a bi-ligand–drug conjugate (Bi-XDC) as late line therapy for patients with metastatic castration resistant prostate cancer (mCRPC)[J]. 2025.